Response to the Letter to the Editor from Valdemar Grill et al: "Islet Function and Insulin Sensitivity in Latent Autoimmune Diabetes in Adults Taking Sitagliptin: A Randomized Trial".

Szczegóły
Comments

Tytuł:: Response to the Letter to the Editor from Valdemar Grill et al: "Islet Function and Insulin Sensitivity in Latent Autoimmune Diabetes in Adults Taking Sitagliptin: A Randomized Trial".
Autorzy:: Liang H; National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.; Affiliated Dongguan People's Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, Guangdong, China.
Yang L; National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Wang X; Division of Endocrinology, Metabolism and Nutrition, Rutgers University-Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
Zhou Z; National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Źródło:: The Journal of clinical endocrinology and metabolism [J Clin Endocrinol Metab] 2021 Sep 27; Vol. 106 (10), pp. e4304-e4305.
Typ publikacji:: Letter; Comment
Język:: English
Imprint Name(s):: Publication: 2017- : New York : Oxford University Press
Original Publication: Springfield, Ill. : Charles C. Thomas
MeSH Terms:: Diabetes Mellitus, Type 1*/drug therapy
Insulin Resistance*
Latent Autoimmune Diabetes in Adults*/drug therapy
Adult ; Humans ; Hypoglycemic Agents/adverse effects ; Sitagliptin Phosphate/adverse effects
References:: Diabetologia. 2008 Apr;51(4):632-40. (PMID: 18292985)
J Clin Endocrinol Metab. 2021 Mar 25;106(4):e1529-e1541. (PMID: 33475138)
J Clin Endocrinol Metab. 2021 Sep 27;106(10):e4296-e4297. (PMID: 34114012)
Diabetes Obes Metab. 2019 Oct;21(10):2219-2227. (PMID: 31148332)
Diabetes Care. 2004 Jun;27(6):1487-95. (PMID: 15161807)
Substance Nomenclature:: 0 (Hypoglycemic Agents)
TS63EW8X6F (Sitagliptin Phosphate)
Entry Date(s):: Date Created: 20210611 Date Completed: 20211111 Latest Revision: 20211111
Update Code:: 20240104
PubMed Central ID:: PMC8475198
DOI:: 10.1210/clinem/dgab413
PMID:: 34114619
: Opinia redakcyjna

Comment on: J Clin Endocrinol Metab. 2021 Mar 25;106(4):e1529-e1541. (PMID: 33475138)
Comment on: J Clin Endocrinol Metab. 2021 Sep 27;106(10):e4296-e4297. (PMID: 34114012)

Informacja